MedTrace Logo

TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma

NCT01869088 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 266

Last updated 2017-03-16

No results posted yet for this study

Summary

The purpose of this study is to determine if TACE plus Recombinant Human Adenovirus Type 5 Injection will improve outcome in patients with advanced hepatocellular carcinoma (HCC) not amenable to surgery or local ablative therapy.

Conditions

Interventions

DRUG

Recombinant Human Adenovirus Type 5 Injection

After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0\*1011vp：0.5ml\*3） will be first infused through the target artery

PROCEDURE

Transartery Chemoembolization

Transartery chemoembolization with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Ming Shi, MD · Cancer Center, Sun Yat-set University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01869088 on ClinicalTrials.gov